ABSTRACT
AIMS/HYPOTHESIS: This study aimed to identify the expression of angiotensin II receptors in isolated human islets and beta cells and to examine the functional consequences of their activation. MATERIALS AND METHODS: Single-cell RT-PCR was used to identify whether human islet cells express mRNA for type 1 angiotensin II receptors (AT(1)), and western blotting was used to determine AT(1) protein expression by human islets and MIN6 beta cells. We measured changes in intracellular calcium by microfluorimetry using Fura 2-loaded MIN6 cells and human islet cells. Dynamic insulin secretory responses were determined by RIA following perifusion of human islets and MIN6 cells. RESULTS: Human islets expressed mRNAs for both the angiotensin precursor, angiotensinogen, and for angiotensin-converting enzyme. In addition, human and mouse beta cells expressed AT(1). These were functionally coupled to increases in intracellular calcium, which occurred at least in part through phospholipase-C-sensitive mechanisms and calcium influx through voltage-operated calcium channels. Short-term exposure of human islets and MIN6 cells to angiotensin II caused a rapid, short-lived initiation of insulin secretion at 2 mmol/l glucose and potentiation of insulin secretion induced by glucose (at 8 and 16.7 mmol/l). CONCLUSIONS/INTERPRETATION: These data demonstrate that the AT(1) is expressed by beta cells and that angiotensin II effects a short-lived and direct stimulation of human and mouse beta cells to promote insulin secretion, most probably through elevations in intracellular calcium. Locally produced angiotensin II may be important in regulating a coordinated insulin secretory response from beta cells.
Subject(s)
Angiotensin II/pharmacology , Insulin/metabolism , Islets of Langerhans/drug effects , Islets of Langerhans/metabolism , Receptors, Angiotensin/physiology , Angiotensin Amide/pharmacology , Angiotensin II/physiology , Angiotensinogen/genetics , Angiotensinogen/physiology , Animals , Blotting, Western , Calcium/analysis , Cell Line , Cells, Cultured , Fluorometry , Gene Expression Regulation , Glucose/pharmacology , Humans , Imidazoles/pharmacology , Insulin Secretion , Insulin-Secreting Cells/chemistry , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/metabolism , Islets of Langerhans/cytology , Mice , Nifedipine/pharmacology , Peptidyl-Dipeptidase A/genetics , Peptidyl-Dipeptidase A/physiology , Pyridines/pharmacology , RNA, Messenger/analysis , RNA, Messenger/genetics , Receptors, Angiotensin/analysis , Receptors, Angiotensin/genetics , Reverse Transcriptase Polymerase Chain Reaction , Saralasin/pharmacologyABSTRACT
It has previously been suggested that ACTH and ACTH-related peptides may act as paracrine modulators of insulin secretion in the islets of Langerhans. We have, therefore, examined the expression and function of the ACTH receptor (the melanocortin 2 receptor, MC2-R) in human and mouse primary islet tIssue and in the MIN6 mouse insulinoma cell line. Mouse MC2-R mRNA was detected in both MIN6 cells and mouse islet tIssue by PCR amplification of cDNA. In perifusion experiments with MIN6 pseudo-islets, a small, transient increase in insulin secretion was obtained when ACTH(1-24) (1 nM) was added to medium containing 2 mM glucose (control) but not when the medium glucose content was increased to 8 mM. Further investigations were performed using static incubations of MIN6 cell monolayers; ACTH(1-24) (1 pM-10 nM) provoked a concentration-dependent increase in insulin secretion from MIN6 monolayer cells that achieved statistical significance at concentrations of 1 and 10 nM (150 +/- 13.6% basal secretion; 187 +/- 14.9% basal secretion, P<0.01). Similar responses were obtained with ACTH(1-39). The phosphodiesterase inhibitor IBMX (100 microM) potentiated the responses to sub-maximal doses of ACTH(1-24). Two inhibitors of the protein kinase A (PKA) signaling pathway, Rp-cAMPS (500 microM) and H-89 (10 microM), abolished the insulin secretory response to ACTH(1-24) (0.5-10 nM). Treatment with 1 nM ACTH(1-24) caused a small, statistically significant increase in intracellular cAMP levels. Secretory responses of MIN6 cells to ACTH(1-24) were also influenced by changes in extracellular Ca2+ levels. Incubation in Ca2+-free buffer supplemented with 0.1 mM EGTA blocked the MIN6 cells' secretory response to 1 and 10 nM ACTH(1-24). Similar results were obtained when a Ca2+ channel blocker (nitrendipine, 10 microM) was added to the Ca2+-containing buffer. ACTH(1-24) also evoked an insulin secretory response from primary tIssues. The addition of ACTH(1-24) (0.5 nM) to perifusions of mouse islets induced a transient increase in insulin secretion at 8 mM glucose. Perifused human primary islets also showed a secretory response to ACTH(1-24) at basal glucose concentration (2 mM) with a rapid initial spike in insulin secretion followed by a decline to basal levels. Overall the results demonstrate that the MC2-R is expressed in beta-cells and suggest that activation of the receptor by ACTH initiates insulin secretion through the activation of PKA in association with Ca2+ influx into beta-cells.
Subject(s)
Adrenocorticotropic Hormone/pharmacology , Cyclic AMP/analogs & derivatives , Insulin/metabolism , Islets of Langerhans/metabolism , Paracrine Communication , Sulfonamides , 1-Methyl-3-isobutylxanthine/pharmacology , Animals , Calcium Channel Blockers/pharmacology , Cell Line , Cells, Cultured , Cyclic AMP/pharmacology , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Dose-Response Relationship, Drug , Humans , Insulin Secretion , Insulinoma/metabolism , Islets of Langerhans/drug effects , Isoquinolines/pharmacology , Mice , Nitrendipine/pharmacology , Phosphodiesterase Inhibitors/pharmacology , RNA, Messenger/analysis , Receptor, Melanocortin, Type 2/genetics , Receptor, Melanocortin, Type 2/metabolism , Stimulation, Chemical , Thionucleotides/pharmacologyABSTRACT
Y1 adrenocortical cells respond to activators of the cyclic AMP-dependent protein kinase (PKA) signalling pathway not only with increases in steroid secretion but also with a characteristic change in cell morphology from flat and adherent to round and loosely attached. This change of shape, which may facilitate cholesterol transport to the mitochondrion, requires tyrosine dephosphorylation of the focal adhesion protein, paxillin, and can be blocked by inhibitors of phosphotyrosine phosphatase (PTP) activity. In a previous study we demonstrated that inhibition of phosphoserine/threonine phosphatase 1 and 2A (PP1/2A) activities caused a similar morphological response to PKA activation whilst opposing the effects on steroid production. We have now investigated the responses to PKA activation and inhibition of PP1/2A and used PTP inhibitors to examine the relationship between the morphological changes and enhanced steroid production. Both forskolin (FSK) and the PP1/2A inhibitor, calyculin A (CA), caused rapid and extensive rounding of Y1 cells. FSK-induced cell rounding was reversible and accompanied by a reduction in the tyrosine phosphorylation of paxillin. Rounding was prevented by the PTP inhibitors pervanadate (PV) and calpeptin (CP) and was associated with the maintained tyrosine phosphorylation of paxillin. In contrast, CA-induced cell rounding was not reversible over a 2-h period and was not affected by the presence of PTP inhibitors, and CA had no effect on the tyrosine phosphorylation of paxillin. Although neither CA nor FSK produced any gross changes in cell viability as judged by Trypan Blue exclusion or mitochondrial activity, CA-treated cells showed a marked reduction in total protein synthesis assessed by (35)S-incorporation. The effects of FSK and the PTP inhibitors on cell rounding were reflected in their effects on steroid production since PV and CP also inhibited FSK-stimulated steroid production. These results suggest that the mechanism through which inhibition of PP1/2A activities induces morphological changes in Y1 cells is fundamentally different from that seen in response to activation of PKA. They are consistent with PKA-induced shape changes in adrenocortical cells being mediated through increased PTP activity and the dephosphorylation of paxillin, and support the view that the morphological and functional responses to PKA activation in steroidogenic cells are intimately linked.
Subject(s)
Adrenal Cortex/metabolism , Adrenal Cortex/pathology , Colforsin/pharmacology , Cyclic AMP-Dependent Protein Kinases/metabolism , Oxazoles/pharmacology , Phosphoprotein Phosphatases/antagonists & inhibitors , Animals , Cell Size/drug effects , Cytoskeletal Proteins/metabolism , Dipeptides/pharmacology , Enzyme Activation , Enzyme Inhibitors/pharmacology , Marine Toxins , Mice , Paxillin , Phosphoproteins/metabolism , Phosphorylation , Pregnenolone/biosynthesis , Protein Phosphatase 1 , Protein Tyrosine Phosphatases/antagonists & inhibitors , Tumor Cells, Cultured , Vanadates/pharmacologyABSTRACT
Cyclic AMP-dependent expression of the steroidogenic acute regulatory (StAR) protein is thought to be the controlling step for steroid production, but the mechanisms through which external signals are translated into increased transcription of the StAR gene are unknown. We demonstrate that cyclic AMP-induced steroid synthesis is dependent upon the phosphorylation and activation of ERKs and that ERK activation results in enhanced phosphorylation of SF-1 and increased steroid production through increased transcription of the StAR gene. Adenylate cyclase activation with forskolin (FSK) caused a time-dependent increase in ERK activity and translocation from cytoplasm to nucleus, which correlated with an increase in StAR mRNA levels, StAR protein accumulation, and steroidogenesis. Similarly, ERK inhibition led to a reduction in the levels of FSK-stimulated StAR mRNA, StAR protein, and steroid secretion. These effects were attributed to the finding that ERK activity is required for SF-1 phosphorylation, a transcription factor required for the regulation of StAR gene transcription. This conclusion was supported by our demonstration of an ERK-dependent increase in the binding of SF-1 from FSK-treated Y1 nuclei to three consensus double-stranded DNA sequences from the StAR promoter region. These observations suggest that the activation of ERK2/1 by increasing cAMP is an obligatory and regulated stage in the stimulation of steroid synthesis by cyclic AMP-generating stimuli.
Subject(s)
Cyclic AMP/physiology , Mitogen-Activated Protein Kinases/physiology , Phosphoproteins/genetics , Steroids/biosynthesis , Transcription, Genetic , Animals , Cyclic AMP-Dependent Protein Kinases/physiology , DNA-Binding Proteins/metabolism , Fushi Tarazu Transcription Factors , Homeodomain Proteins , Mice , Phosphoproteins/metabolism , Phosphorylation , Receptors, Cytoplasmic and Nuclear , Steroidogenic Factor 1 , Transcription Factors/metabolismABSTRACT
The function of the adrenal cortex of the marmoset monkey Callithrix jacchus has been investigated. In common with other New World primates, these animals seem to be glucocorticoid resistant. Blood and adrenal glands were obtained from male and female animals under terminal pentobarbitone anesthesia. Dispersed adrenal cell preparations were obtained by treatment with collagenase and incubated with ACTH(1-24), (0.1-1000 nM) angiotensin II (0.1-1000 nM), dibutyryl cyclic AMP (dbcAMP; 30-1000 microM), and forskolin (FSK; 1-30 microM). Plasma cortisol levels (2113 +/- 449 ng/ml male; 3858 +/- 429 ng/ml female) were found to be 10- to 20-fold higher than those quoted for Old World primates and man. The cell preparations showed no significant response to any dose of ACTH tested (0.1-1000 nM), although addition of exogenous precursor (22R-hydroxycholesterol, 2.5 microM) resulted in an increased yield of cortisol and aldosterone. Cyclic AMP production was increased in response to forskolin (1-30 microM) but not ACTH(1-24) (1-1000 nM). In addition, dose-related responses to angiotensin II (maximal stimulation of 316 +/- 49% basal aldosterone at 100 nM angiotensin II), dbcAMP (maximal stimulation of 449 +/- 24% basal cortisol at 300 microM dbcAMP), and forskolin (maximal stimulation of 394 +/- 31% basal cortisol at 10 microM FSK) were obtained. The lack of a response in vitro to ACTH in C. jacchus cannot, therefore, be attributed either to general failure of the cells or to defects in postreceptor signaling mechanisms. The results suggest that there is a reduction in adrenal ACTH receptor number or affinity, with a high basal production rate in vivo maintaining the elevated plasma cortisol levels.
Subject(s)
Adrenal Cortex/physiology , Callithrix/physiology , Adrenal Cortex/anatomy & histology , Adrenal Cortex/drug effects , Adrenocorticotropic Hormone/administration & dosage , Adrenocorticotropic Hormone/pharmacology , Aldosterone/blood , Angiotensin II/administration & dosage , Angiotensin II/pharmacology , Animals , Bucladesine/pharmacology , Colforsin/administration & dosage , Colforsin/pharmacology , Cyclic AMP/biosynthesis , Dose-Response Relationship, Drug , Female , Hydrocortisone/blood , MaleABSTRACT
The rate-limiting step in steroidogenesis is the transport of cholesterol into the mitochondria, and this is controlled by the steroidogenic acute regulatory (StAR) protein. We have previously shown that inhibition of phosphoprotein phosphatase 1 and 2A (PP1/2A) activities with the PP1/2A inhibitor calyculin A selectively reduces StAR protein expression and thus inhibits the synthesis of steroid hormones. The aim of this study was to determine whether this inhibition of StAR protein expression occurs at the level of transcription of StAR mRNA. We have used a competitive reverse transcription-polymerase chain reaction (RT-PCR) technique to determine whether inhibition of PP1/2A activities has any effect on the levels of StAR mRNA. Exposure of Y1 cells to forskolin significantly increased the expression of StAR mRNA and this forskolin-induced increase was reduced after exposure to Cal A at levels similar to those seen in the controls. These results suggest that cyclic AMP-induced increases in StAR mRNA levels are dependent upon phosphoprotein phosphatase activities.
Subject(s)
Gene Expression Regulation , Phosphoprotein Phosphatases/metabolism , Phosphoproteins/genetics , Steroids/biosynthesis , Transcription, Genetic/genetics , Adrenal Cortex/cytology , Adrenal Cortex/drug effects , Adrenal Cortex/metabolism , Animals , Cell Line , Colforsin/antagonists & inhibitors , Colforsin/pharmacology , Dose-Response Relationship, Drug , Gene Expression Regulation/drug effects , Marine Toxins , Mice , Oxazoles/pharmacology , Phosphoprotein Phosphatases/antagonists & inhibitors , Pregnenolone/metabolism , Protein Phosphatase 1 , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Steroids/metabolism , Transcription, Genetic/drug effectsABSTRACT
In addition to the well-documented role of protein kinases in the regulation of steroid production, phosphoprotein phosphatase (PP) activity is required for steroidogenesis. In the present study, we have used the mouse Y1 adrenocortical cell line to identify the site of action of PPs on steroid production by measuring the effects of PP inhibition on the expression of the steroidogenic acute regulatory (StAR) protein and on steroid production. Forskolin-induced activation of cyclic AMP-dependent protein kinase (PKA) enhanced steroidogenesis and this was accompanied by an increased expression of StAR protein. Both steroidogenesis and StAR protein expression were inhibited by two structurally dissimilar inhibitors of PP1 and PP2A activities, okadaic acid and calyculin A. These results suggest that inhibition of PP1 and PP2A inhibits steroid production by preventing the expression of the StAR protein, implicating PP1/2A dephosphorylation reactions as important regulators of stimulus-dependent StAR protein expression, and thus of steroidogenesis.
Subject(s)
Adrenal Cortex/metabolism , Cyclic AMP-Dependent Protein Kinases/metabolism , Cyclic AMP/metabolism , Phosphoproteins/biosynthesis , Protein Tyrosine Phosphatases/metabolism , Steroids/biosynthesis , Animals , Cell Line , Colforsin/pharmacology , Enzyme Inhibitors/pharmacology , Hydroxycholesterols/pharmacology , Isoenzymes/metabolism , Kinetics , Marine Toxins , Mice , Okadaic Acid/pharmacology , Oxazoles/pharmacology , Phosphoproteins/genetics , Pregnenolone/pharmacology , Progesterone/metabolismABSTRACT
Y1 adrenocortical cells respond to forskolin stimulation with increases in steroid secretion and change of shape. The rapid rounding of flat, adherent cells which occurs is known to involve dephosphorylation of the focal adhesion protein, paxillin. We have investigated the effects of a tyrosine phosphatase inhibitor, calpeptin (CP) on steroidogenesis and shape change in Y1 cells. Forskolin treatment (FSK, 2 microM) caused marked rounding of Y1 cells (FSK = 76.3 +/- 1.5% cells rounded after 30 minutes, untreated = 2.9 +/- 0.7 % rounded); calpeptin pretreatment (CP; 100 ug/ml) had little effect on shape (9.6 +/- 2.4% rounded) but blocked the rounding response to FSK (32.1 +/- 2.1% rounded. Calpetin also eliminated the steroidogenic response to FSK ( FSK = 242 +/- 14% control ; FSK + CP = 113 +/- 18% control ) without affecting production of steroid from membrane permeant 22R-OH-cholesterol. The results support the view that dephosphorylation of paxillin is important in the rounding response and provide evidence for the involvement of tyrosine-phosphatase activity in cyclic AMP-stimulated steroidogenesis in Y1 cells.
Subject(s)
Adrenal Cortex Neoplasms/metabolism , Adrenal Cortex Neoplasms/pathology , Dipeptides/pharmacology , Enzyme Inhibitors/pharmacology , Protein Tyrosine Phosphatases/antagonists & inhibitors , Steroids/biosynthesis , Animals , Cell Size/drug effects , Colforsin/pharmacology , Steroids/antagonists & inhibitors , Tumor Cells, CulturedSubject(s)
Adrenal Cortex Neoplasms/metabolism , Enzyme Inhibitors/pharmacology , Oxazoles/pharmacology , Phosphoprotein Phosphatases/antagonists & inhibitors , Phosphoproteins/metabolism , Steroids/biosynthesis , Adrenal Cortex Neoplasms/pathology , Animals , Colforsin/pharmacology , Marine Toxins , Mice , Tumor Cells, Cultured/drug effectsABSTRACT
The involvement of protein kinases in the signal transduction pathways controlling adrenal steroidogenesis is well established, and the phosphorylation of substrates by cAMP-dependent protein kinase is a major mechanism in ACTH action. However, the possibility that protein phosphatases (PPs) might also be involved in this process has not been investigated. The aim of this study was, therefore, to measure the function, expression and enzymic activity of PPs in zona glomerulosa (ZG) and zona fasciculata/reticularis (ZFR) tissue from the rat adrenal cortex. Immunoblot analysis using specific antisera demonstrated the presence in whole adrenals and capsules of PP type 1 (PP1) migrating with an apparent molecular mass of 37 kDa, and PP type 2A (PP2A) migrating with apparent molecular masses of 38 and 31 kDa. The PP inhibitors, okadaic acid (OA), calyculin A (CA), tautomycin and microcystin RR, caused a reduction in PP activity in vitro, at doses between 1 nM and 1 microM. In addition, treatment of ZG cells with the adenylate cyclase stimulator, forskolin (10 microM) resulted in a significant reduction in PP activity. The effects of CA and OA on steroid secretion by ZG and ZFR cells were also investigated. Neither CA nor OA had any effect on basal steroid secretion or on yields of steroid obtained from 22R-hydroxycholesterol at doses between 1 and 100 nM. However, both OA and CA (10 and 100 nM respectively) significantly reduced ACTH-stimulated aldosterone and corticosterone production by ZG and ZFR cells. CA and OA (10 and 100 nM respectively) also reduced steroid secretion by cells stimulated by forskolin (10 microM) or dibutyryl cAMP (200 microM). These results suggest that PPs may be involved in the intracellular mechanisms through which adrenocortical steroidogenesis is regulated, acting at a point after cAMP generation and action, but proximal to the side-chain cleavage of cholesterol.
Subject(s)
Adrenal Cortex Hormones/biosynthesis , Adrenal Cortex/enzymology , Phosphoric Monoester Hydrolases/metabolism , Phosphothreonine/metabolism , Pyrans , Signal Transduction/physiology , Spiro Compounds , Adrenal Cortex/drug effects , Adrenal Cortex/metabolism , Adrenocorticotropic Hormone/pharmacology , Aldosterone/biosynthesis , Animals , Antifungal Agents/pharmacology , Bucladesine/pharmacology , Cells, Cultured , Colforsin/pharmacology , Corticosterone/biosynthesis , Enzyme Inhibitors/pharmacology , Immunoblotting , Male , Marine Toxins , Microcystins , Okadaic Acid/pharmacology , Oxazoles/pharmacology , Peptides, Cyclic/pharmacology , Phosphoric Monoester Hydrolases/antagonists & inhibitors , Rats , Rats, Sprague-Dawley , Stimulation, ChemicalABSTRACT
The role played by cyclic AMP (cAMP)-dependent protein kinases (PKAs) in rat adrenal steroidogenesis has been investigated using cAMP analogues which show partial selectivity for the type I and type II PKA isoenzymes. These were aminohexylamino-cAMP (AHA-cAMP; selective for site 1 on type I PKA), N6-benzoyl-cAMP (BZ-cAMP; selective for site 2 on PKA types I and II) and 8-thiomethyl-cAMP (TM-cAMP; selective for site 1 on type II PKA). Positive cooperativity exists between the two nucleotide-binding sites, thus the presence of type I PKA was inferred when synergistic increases in corticosteroid production were obtained with AHA-cAMP plus BZ-cAMP and that of type II PKA when synergistic increases were obtained with TM-cAMP plus BZ-cAMP. The effects of AHA-cAMP, TM-cAMP and BZ-cAMP (10-100 mumol/l) on aldosterone production by glomerulosa cell preparations and corticosterone production by fasciculata/reticularis cell preparations were compared. Dose-related stimulation of steroid production was obtained with each cAMP analogue in both types of cell preparation. Experiments were performed using the cAMP analogues in combination at doses which gave minimal stimulation individually. Cells were incubated with AHA-cAMP (66 and 100 mumol/l) or TM-cAMP (15, 30 and 45 mumol/l) in the presence and absence of 15 mumol BZ-cAMP/l. Synergistic responses were obtained with both analogue pairs in both cell types.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Adrenal Cortex Hormones/biosynthesis , Adrenal Cortex/enzymology , Cyclic AMP-Dependent Protein Kinases/physiology , Cyclic AMP/physiology , Isoenzymes/physiology , Adrenal Cortex/drug effects , Adrenal Cortex/metabolism , Animals , Cells, Cultured , Cyclic AMP/analogs & derivatives , Cyclic AMP-Dependent Protein Kinase Type II , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Drug Synergism , Female , Male , Rats , Rats, Sprague-Dawley , Zona Glomerulosa/drug effects , Zona Glomerulosa/enzymology , Zona Glomerulosa/metabolismABSTRACT
Chronic treatment with high doses of ACTH leads to marked reduction in aldosterone biosynthesis and secretion both in vivo and in vitro. In contrast, it has been reported that peripheral plasma aldosterone levels may be elevated following prolonged ACTH treatment. The present study attempts to determine the reason(s) for this apparently paradoxical finding. ACTH treatment (40 micrograms/100 g body weight) of male Sprague-Dawley rats for 7 days caused a decrease of more than 90% in aldosterone secretion into the adrenal vein in vivo and aldosterone production by intact adrenal capsules incubated in vitro. In contrast, peripheral plasma aldosterone levels appeared to be increased when measured by radioimmunoassay using two different polyclonal antibodies (antibody 1 (AB1) raised against aldosterone-3-carboxymethyloxime-bovine serum albumin (BSA) and antibody 2 (AB2) raised against aldosterone-21-hemisuccinate-BSA). However, when a highly specific monoclonal antibody (raised against aldosterone-3-carboxymethyloxime-BSA and showing low cross-reactivity to aldosterone metabolites) was used, peripheral plasma aldosterone levels appeared to be reduced in ACTH-treated rats. Following chromatographic fractionation of peripheral plasma, significantly more material with aldosterone-like immuno-reactivity, but which was less polar than authentic aldosterone in chromatographic mobility, was detected in the fractions using antibodies AB1 and AB2. The absence of this material from fractions of adrenal vein plasma leads us to infer that this material is generated in the peripheral circulation, probably as a result of hepatic metabolism. In addition, the overall metabolic clearance rate (MCR) of [3H] aldosterone was found to be significantly decreased following prolonged ACTH treatment. We conclude that the seemingly discrepant findings with regard to the effects of chronic ACTH treatment on peripheral plasma aldosterone levels and the secretion of aldosterone in vivo can be reconciled by (1) the changes in the overall MCR of aldosterone and (2) the generation of increased quantities of aldosterone metabolites such as 5 alpha-dihydroaldosterone and 3 alpha, 5 beta-tetrahydroaldosterone which show significant cross-reactivity with some aldosterone antibodies.
Subject(s)
Adrenal Glands/drug effects , Adrenocorticotropic Hormone/pharmacology , Aldosterone/metabolism , Adrenal Glands/blood supply , Adrenal Glands/metabolism , Aldosterone/biosynthesis , Aldosterone/blood , Aldosterone/pharmacokinetics , Animals , Chromatography, High Pressure Liquid , Male , Metabolic Clearance Rate/drug effects , Radioimmunoassay/methods , Rats , Rats, Sprague-DawleyABSTRACT
It is possible that some of the effects of sodium pentobarbitone on the hypothalamo-pituitary-adrenal axis in the intact animal may be attributable to direct actions on the adrenal cortex. The effects of the barbiturate on steroid production by rat adrenal preparations in vitro have therefore been examined. In zona glomerulosa cells, pentobarbitone inhibited basal steroid production in a dose-related fashion. For aldosterone and corticosterone, the doses required for 50% inhibition of production (IC50) were 1.2 mmol pentobarbitone/l and 3.7 mmol/l respectively. Steroidogenesis was inhibited at lower levels of pentobarbitone in the presence of 1 nmol ACTH/l (IC50 = 0.5 mmol pentobarbitone/l for aldosterone and 2.2 mmol/l for corticosterone). In zona fasciculata/reticularis cells, production of corticosterone was similarly reduced with an IC50 of 2.8 mmol pentobarbitone/l for basal production and 1.3 mmol/l for ACTH-stimulated production. The dose-related increases in corticosterone production produced by ACTH (0.1-1000 pmol/l) or dibutyryl cyclic AMP (0.1-1.0 mmol/l) were also eliminated in the presence of 2 mmol pentobarbitone/l. The effects of pentobarbitone (1-4 mmol/l) on the production of pregnenolone and deoxycorticosterone (DOC) were also studied. In zona fasciculata/reticularis cells, the responses of both pregnenolone and DOC were bell-shaped with increases at 1 mmol pentobarbitone/l, which fell back to control levels at 4 mmol pentobarbitone/l. Stimulation of DOC, accompanied by decreases in aldosterone and corticosterone production, was also seen in zona glomerulosa cells at 1 mmol pentobarbitone/l.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Adrenal Cortex Hormones/biosynthesis , Adrenal Cortex/drug effects , Pentobarbital/pharmacology , Adrenal Cortex/metabolism , Adrenocorticotropic Hormone/pharmacology , Aldosterone/biosynthesis , Animals , Bucladesine/pharmacology , Cells, Cultured , Corticosterone/biosynthesis , Depression, Chemical , Desoxycorticosterone/biosynthesis , Dose-Response Relationship, Drug , Female , Male , Pregnenolone/biosynthesis , Progesterone/metabolism , Rats , Rats, Inbred StrainsABSTRACT
The rat adrenal cortex contains quantities of dopamine that are compatible with its function as a neurotransmitter, suggesting that locally released dopamine may act as a neuroregulator within the gland. This possibility has been tested by comparing the effects of dopamine on aldosterone secretion in the perfused adrenal with the effects of stimuli designed to provoke the release of intraglandular dopamine. Infusion of dopamine (0.1-100 mumol/l for 10-min periods) into the isolated perfused rat adrenal gland resulted in a transient, dose-related reduction of aldosterone secretion to a minimum of approximately 50% of the basal value at 1 mumol dopamine/l (ratio of experimental to control measurements, R = 0.53 +/- 0.06 (S.E.M.); n = 5). In contrast, dopamine (1-100 mumol/l) had no effect on aldosterone production by dispersed zona glomerulosa cell preparations incubated in vitro. The effects of changes in K+ concentration (3.9-52 mmol/l) on aldosterone secretion in the perfused gland and dispersed cell preparations were also compared. A similar bell-shaped dose-response relationship was seen in both preparations between 6 and 32 mmol K+/l, with a maximum at 8.4 mmol K+/l and a return to control values with 16, 24 or 32 mmol K+/l. However, infusion of media with very high K+ concentrations (42 or 52 mmol K+/l) reduced the secretion of aldosterone by the perfused gland to approximately 50% of the basal value (R = 0.51 +/- 0.05, n = 9; R = 0.49 +/- 0.08, n = 9; respectively) but produced no change in aldosterone production by zona glomerulosa cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Adrenal Glands/metabolism , Aldosterone/metabolism , Dopamine/physiology , Potassium/physiology , Adrenal Glands/drug effects , Adrenal Glands/physiology , Animals , Dopamine/pharmacology , Dose-Response Relationship, Drug , Electrophysiology , Male , Organ Culture Techniques , Potassium/pharmacology , Rats , Rats, Inbred StrainsABSTRACT
The cellular mechanisms for aldosterone biosynthesis are incompletely understood. Although the enzymes involved are now well characterized, the dynamics of aldosterone secretion in a variety of rat adrenal preparations are not consistent with the concept that freshly synthesized corticosterone is an important intermediate. In whole glomerulosa tissue preparations, aldosterone is more readily formed from endogenous precursors than from an added radioactive precursor, such as [3H]pregnenolone, and in the in situ perfused gland preparation, aldosterone responses to stimulation, for example by ACTH, are significantly more rapid than those of corticosterone, suggesting a tissue source of steroid substrate for aldosterone production other than corticosterone. The only steroid which is stored in rat adrenal glomerulosa tissue to any extent is 18-hydroxydeoxycorticosterone (18-OH-DOC), and this pool has been located in plasma membrane fractions. It is lost on preparation of collagenase dispersed glomerulosa cells. Since dispersed glomerulosa cell preparations produce significantly less aldosterone, relative to corticosterone, than incubated intact whole glomerulosa, it is plausible that this tissue pool (which is not found in the inner zones) is the immediate precursor for aldosterone formation. Further evidence shows that trypsin, which stimulates aldosterone (and 18-hydroxycorticosterone) production in rat intact glomerulosa tissue, but not in dispersed cells, stimulates translocation of protein kinase C to the plasma membrane. It is plausible that one function of protein kinase C in the rat adrenal zona glomerulosa is to mobilize membrane sequestered 18-OH-DOC for conversion to aldosterone.
Subject(s)
Aldosterone/biosynthesis , Zona Glomerulosa/metabolism , Animals , Catalysis , Corticosterone/biosynthesis , Cytochrome P-450 CYP11B2 , Cytochrome P-450 Enzyme System/metabolism , Desoxycorticosterone/analogs & derivatives , Desoxycorticosterone/biosynthesis , In Vitro Techniques , Rats , Steroid Hydroxylases/metabolism , Trypsin/physiology , Zona Glomerulosa/enzymologyABSTRACT
The actions of forskolin have been investigated to determine to what extent its effects on steroidogenesis in rat adrenal preparations are dependent on activation of adenylate cyclase. In zona glomerulosa preparations, stimulation of both aldosterone and corticosterone production was obtained at concentrations of forskolin between 1 and 10 mumol/l. The effects of 10 mumol forskolin/l were additive with those of low doses (1 pmol/l) of corticotrophin (ACTH), but not with those of high doses (1 nmol/l) of ACTH. In contrast, in zona fasciculata/reticularis cells, doses of forskolin up to 10 mumol/l produced no significant stimulation of corticosterone production either alone or in the presence of ACTH (1 pmol/l and 1 nmol/l). The response to 1 nmol ACTH/l was attenuated in the presence of forskolin (10 mumol/l) in both zona glomerulosa and zona fasciculata/reticularis cell preparations. Cyclic AMP production increased progressively with dose up to 100 mumol forskolin/l in zona glomerulosa cells, whereas corticosterone production was maximal between 10 and 30 mumol forskolin/l and decreased at 100 mumol forskolin/l. In zona fasciculata/reticularis cells, cyclic AMP production was also increased by forskolin (1 and 10 mumol/l). The stimulation of zona glomerulosa steroidogenesis by forskolin (1-10 mumol/l) and ACTH (1-100 pmol/l) were both reduced by the adenylate cyclase inhibitor, N6-phenylisopropyladenosine (100 mumol/l). The calcium channel inhibitor, nifedipine, only reduced the steroidogenic response to forskolin (3 mumol/l) at doses of 300 mumol/l whereas the response to 8.4 mmol K+/l was inhibited at 10 mumol nifedipine/l.(ABSTRACT TRUNCATED AT 250 WORDS)